key: cord-330916-s99ayg1j
authors: Hernandez, Adrian V.; Roman, Yuani M.; Pasupuleti, Vinay; Barboza, Joshuan J.; White, C. Michael
title: Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
date: 2020-07-15
journal: Ann Intern Med
DOI: 10.7326/l20-0945
sha: 
doc_id: 330916
cord_uid: s99ayg1j

nan

Published reports of 3 studies previously available as preprints became available (2-4), enabling more thorough assessment for risk of bias. The risk of bias is now determined to be serious for Yu and colleagues' study (4) , remains high for Tang and colleagues' study (2), and changed from moderate to serious for Mahé vas and colleagues' study (3) . We found 1 new randomized controlled trial (RCT) with high risk of bias (5), 1 new cohort study with moderate risk of bias (6) , and 4 cohort studies that each had serious risk of bias (7) (8) (9) (10) . An additional large cohort study was published and subsequently retracted due to concerns about the veracity of the data (11, 12) and was not considered further. Press releases reported 3 large RCTs (RECOVERY, SOLIDARITY-WHO, and ORCHID-NIH) that ceased enrollment for the hydroxychloroquine versus control comparison early because of lack of efficacy in preliminary analyses (13) (14) (15) . These trials had strong study designs, but other than press releases, no reports were available to assess.

The only new data on chloroquine came from Chen and colleagues' aforementioned RCT, which contained a chloroquine group that was compared with a control group (5). This RCT had high risk of bias and observed no deaths or severe disease progression, and all patients in both groups cleared the virus from the upper respiratory tract by day 10 (5). However, clinical recovery took fewer days in the chloroquine group than the control group.

Supplement Tables 1 and 2 (available at Annals.org) provide updated unadjusted outcomes data (1-28). Given the risk of bias for individual studies and the conflicting direction and magnitude of results, the evidence from both RCTs and cohort studies remains insufficiently strong to support a benefit of hydroxychloroquine or chloroquine for treatment of COVID-19 in hospitalized patients. We were unable to identify a pattern by which risk of bias, dosage, duration of therapy, or other factors explained the conflicting findings. The strength of evidence remains insufficient for all safety outcomes.

This update identified 1 new RCT, several new cohort studies, and more complete published reports of studies previously available as preprints; the conclusions are un-changed from the initial review. The newly available evidence has high risk of bias. There is insufficient evidence to support the effectiveness or safety of hydroxychloroquine or chloroquine for the treatment of COVID-19 in hospitalized patients.

The results of the RECOVERY, SOLIDARITY-WHO, and ORCHID-NIH trials could help to more definitively determine the role of this therapy for COVID-19. 

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. Preprint posted online 22

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 inpatients in France. medRxiv. Preprint posted online 16

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

Hydroxychloroquine and tocilizumab therapy for COVID-19 patients -an observational study. medRxiv. Preprint posted online 21

Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-real-world evidence from a federated electronic medical record network. medRxiv. Preprint posted online 12

Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

2 papers about drug therapy for COVID-19 retracted from prestigious journals

/Article/05-20/2-Papers-AboutDrug-Therapy-in-COVID-19-Retracted-From -Prestigious-Journals/58677 on 6

No clinical benefit from use of hydroxychloroquinein hospitalised patients with COVID-19

Accessed at www.who .int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine -and-lopinavir-ritonavir-treatment-arms-for-covid-19 on 6

A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19

Preliminary study of hydroxychloroquine sulfate in treating common coronavirus disease (COVID-19) patients in 2019

Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study. Accessed at www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical %20Outcomes%20of%20Hydroxychlorquine%20in%20Patients%20with %20COVID19

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. Preprint posted online 23

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study. medRxiv. Preprint posted online 2

Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study

Observational study of hydroxychloroquine in hospitalized patients with covid-19

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. Preprint posted online 14

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. Preprint posted online

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Chloroquine diphosphate in two different dosages as adjunctive therapy for hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. Preprint posted online 16

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. medRxiv